Black Diamond Financial LLC Acquires New Stake in Capricor Therapeutics Inc (NASDAQ:CAPR)

Black Diamond Financial LLC purchased a new position in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 277,737 shares of the biotechnology company's stock, valued at approximately $3,833,000. Black Diamond Financial LLC owned approximately 0.61% of Capricor Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. New York State Common Retirement Fund grew its position in shares of Capricor Therapeutics by 625.0% in the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 5,000 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in Capricor Therapeutics during the third quarter worth $161,000. Sassicaia Capital Advisers LLC acquired a new position in Capricor Therapeutics in the third quarter worth $192,000. SG Americas Securities LLC increased its stake in Capricor Therapeutics by 74.8% during the fourth quarter. SG Americas Securities LLC now owns 15,317 shares of the biotechnology company's stock valued at $211,000 after purchasing an additional 6,552 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Capricor Therapeutics by 868.7% during the third quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company's stock worth $269,000 after purchasing an additional 15,872 shares during the period. 21.68% of the stock is owned by institutional investors.

Capricor Therapeutics Trading Down 0.6 %

NASDAQ:CAPR traded down $0.08 during mid-day trading on Thursday, hitting $14.38. The stock had a trading volume of 1,094,585 shares, compared to its average volume of 934,302. The company has a 50 day simple moving average of $14.34 and a 200-day simple moving average of $13.57. The stock has a market capitalization of $653.86 million, a price-to-earnings ratio of -13.57 and a beta of 4.08. Capricor Therapeutics Inc has a 52 week low of $3.52 and a 52 week high of $23.40.

Wall Street Analyst Weigh In

Several research analysts have recently commented on CAPR shares. Cantor Fitzgerald lifted their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an "overweight" rating in a report on Thursday, November 14th. HC Wainwright restated a "buy" rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research note on Thursday, January 2nd. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $34.50.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.